{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:12:33Z","timestamp":1778101953451,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijid.2026.108558","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:05:57Z","timestamp":1773763557000},"page":"108558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Extended nirmatrelvir-ritonavir for persistent COVID-19: Systematic review with individual patient data"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7303-3917","authenticated-orcid":false,"given":"Aresh","family":"Farokhnia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9on Kia","family":"Faro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Frischknecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Eimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tal","family":"Brosh-Nissimov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108558_bib0001","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.cmi.2024.04.009","article-title":"Persistent COVID-19 in immunocompromised patients\u2014Israeli society of infectious diseases consensus statement on diagnosis and management","volume":"30","author":"Meijer","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.ijid.2026.108558_bib0002","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.immuni.2022.09.006","article-title":"SARS-CoV-2 in immunocompromised individuals","volume":"55","author":"DeWolf","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ijid.2026.108558_bib0003","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/cid\/ciab700","article-title":"Incidence, clinical presentation, relapses and outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients treated with anti-CD20 monoclonal antibodies","volume":"74","author":"Calder\u00f3n-Parra","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2026.108558_bib0004","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/fcp.12889","article-title":"Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: molnupiravir, nirmatrelvir, and remdesivir","volume":"37","author":"Yan","year":"2023","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ijid.2026.108558_bib0005","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108558_bib0006","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s15010-023-02138-0","article-title":"Clinical phenotype and outcome of persistent SARS-CoV-2 replication in immunocompromised hosts: a retrospective observational study in the Omicron era","volume":"52","author":"G\u00f6tz","year":"2024","journal-title":"Infection"},{"key":"10.1016\/j.ijid.2026.108558_bib0007","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3390\/v15102066","article-title":"Remdesivir or nirmatrelvir\/ritonavir therapy for Omicron SARS-CoV-2 infection in hematological patients and cell therapy recipients","volume":"15","author":"Pi\u00f1ana","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ijid.2026.108558_bib0008","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2026.108558_bib0009","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.ijid.2026.108558_bib0010","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.ijid.2026.108558_bib0011","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1093\/jac\/dkae234","article-title":"Comment on: Suboptimal response to combination therapy with tixagevimab\/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients","volume":"79","author":"Barone","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108558_bib0012","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.941165","article-title":"A 67-year-old man with chronic lymphocytic leukemia (CLL) on maintenance therapy with Ibrutinib with persistent SARS-CoV-2 infection unresponsive to antiviral treatments","volume":"25","author":"Sanmartin","year":"2024","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.ijid.2026.108558_bib0013","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.medj.2023.08.001","article-title":"Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2","volume":"4","author":"Hirotsu","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.ijid.2026.108558_bib0014","doi-asserted-by":"crossref","first-page":"ofad612","DOI":"10.1093\/ofid\/ofad612","article-title":"A multinational case series describing successful treatment of persistent severe acute Respiratory syndrome coronavirus 2 infection caused by Omicron sublineages with prolonged courses of nirmatrelvir\/ritonavir","volume":"11","author":"Snell","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2026.108558_bib0015","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jiac.2023.12.014","article-title":"Acute acalculous cholecystitis following extended administration of nirmatrelvir\/ritonavir for persistent SARS-CoV-2 infection","volume":"30","author":"Ito","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijid.2026.108558_bib0016","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/1120009X.2024.2367935","article-title":"Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19","volume":"37","author":"Antonello","year":"2025","journal-title":"J Chemother"},{"key":"10.1016\/j.ijid.2026.108558_bib0017","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/cid\/ciac868","article-title":"Successful treatment of prolonged, severe coronavirus disease 2019 lower respiratory tract disease in a B cell acute lymphoblastic leukemia patient with an extended course of remdesivir and nirmatrelvir\/ritonavir","volume":"76","author":"Ford","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108558_bib0018","unstructured":"SmPC Norvir 100 mg film-coated tablets Electronic Medicines Compendium (EMC); n.d. https:\/\/www.medicines.org.uk\/emc\/product\/510\/smpc."},{"key":"10.1016\/j.ijid.2026.108558_bib0019","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S1473-3099(25)00221-X","article-title":"Extended nirmatrelvir\u2013ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial","volume":"25","author":"Weinstein","year":"2025","journal-title":"Lancet Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226001931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226001931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T20:27:36Z","timestamp":1778099256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226001931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":19,"alternative-id":["S1201971226001931"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108558","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended nirmatrelvir-ritonavir for persistent COVID-19: Systematic review with individual patient data","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108558"}}